Liposome refers to a spherical vesicle consisting of more than one lipid bilayers and its interaction in the aqueous phase. The hydrophobic bilayer is constantly repelled by water molecules resulting in a liposome self-assembly. It finds application as a drug delivery agent for delivery pharmaceutical drugs, mRNA vaccines, and DNA vaccines. Additionally, COVID-19 has provided an impetus to the use of liposomes as drug delivery agents, thus decreasing the socio-economic burden. Liposomes find application against fungal diseases, cancer therapy, pain management, viral vaccines, and photodynamic therapy. They are the carriers that have been explored more than any other carrier, due to their various forms right from unilamellar, multi lamellar and giant lamellar. The whole process of liposome drug delivery provides an effective way out of delivering vaccines and genomes due to their targeting ability and corrected gene inputs. The approach results in less side effects as compared to traditional formulations. However, their high cost of production and physical stability act as barriers against market growth.
COVID-19 Impact Analysis
Increase has been witnessed in the demand for medical supplies to take care of infected population. Respiratory support devices such as atomizers, life support machines, oxygen generators, and monitors are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. The need for medical supplies has increased significantly among both from healthcare professionals and civil population for precautionary measures, owing to rise in number of COVID-19 cases worldwide. Manufacturers of these products have a chance to capitalize this increased demand for medical supplies to ensure adequate and continuous supply of personal protective equipment in the market. Therefore, COVID 19 is expected to have a significant impact on the global liposomes drug delivery market.
Top Impacting Factors
- Acceptance of liposomes as nano-carriers is providing pharmaceutical players with enhanced techniques such as nanotechnology to enhance drug release profiles. Companies are expanding their research and development infrastructure to optimize drug delivery capabilities of liposomes.
- Overall enhancements in the understanding of targeted drug delivery systems by various relevant stakeholders, including pharmaceutical firms and government mechanisms might act as an impetus for the growth of use of liposomes as the drug delivery agents.
- Increase in the number of cases of patients suffering from malignant and benign tumors as well as macrophages and the subsequent need of drugs for cure may act as growth drivers for the industry.
- Advantages of liposomes over tradition drug delivery systems such as the ability to carry large drug payloads, biocompatibility, and the self-assembly capability has proved to be a major reason for acceptance of liposome as the drug delivery agent.
- Owing to high cost of production, use of liposomes as regular drug delivery agents may be a far-fetched idea.
- Major limitations of liposome such as a short half-life and low solubility hamper the market growth.
Key Market Trends
- Rise of cancer cases all across North America augments the growth of the global liposome drug delivery market.
- The insights gained from the whole system of using liposomes as drug delivery agents is being used to design liposomes, which can target tissues and cells without the expression of target recognition molecules in its outer membrane. Additional refinements in the liposome drug delivery system may permit selective delivery of therapeutic compounds to sought-after intracellular target areas.
- Liposomes that exhibit very high or very low pH values are being constructed in a way such that dissolved aqueous drugs are charged in the solution.
- Further liposomal studies suggest that they can deliver both hydrophilic and hydrophobic drugs for cancer, antifungal, immunomodulation, and antibacterial diseases.
Key Benefits of the Report
- This study presents the analytical depiction of the targeted liposomes drug delivery industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the testing growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Targeted Liposomes Drug Delivery Report
- Which are the leading players active in the Targeted Liposomes Drug Delivery market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the Targeted Liposomes Drug Delivery market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is Targeted Liposomes Drug Delivery?
- What is the Targeted Liposomes Drug Delivery market prediction in the future?
- What are the current trends and predicted trends?
Targeted Liposomes Drug Delivery Market Report Highlights
| Aspects | Details |
 By Product |
|
 By Technology |
|
 By Application |
|
 By Region |
|
 Key Market Players | Gilead Sciences, Inc., Johnson and Johnson, Astellas Pharma, Inc., Ipsen Pharma, Luye Pharma Group, Novartis AG, Pacira BioSciences, Inc., Celsion Corporation, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited |
Loading Table Of Content...
